{"id":62785,"date":"2026-04-10T13:21:29","date_gmt":"2026-04-10T05:21:29","guid":{"rendered":"https:\/\/flcube.com\/?p=62785"},"modified":"2026-04-10T13:21:30","modified_gmt":"2026-04-10T05:21:30","slug":"oricell-therapeutics-secures-110m-pre-ipo-round-to-advance-first-in-class-car-t-for-liver-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62785","title":{"rendered":"Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer"},"content":{"rendered":"\n<p><strong>Oricell Therapeutics Co., Ltd.<\/strong>, a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has raised <strong>over USD 110 million<\/strong> in a <strong>pre-IPO financing round<\/strong>. The round was co-led by <strong>Vivo Capital<\/strong>, <strong>Beijing Medical and Health Care Industry Investment Fund<\/strong>, <strong>Qiming Venture Partners<\/strong>, and a <strong>leading global healthcare fund<\/strong>, with additional participation from an <strong>international sovereign wealth fund<\/strong>, <strong>E-Town Capital<\/strong>, <strong>Luxin Venture Capital<\/strong>, <strong>NGS Super<\/strong>, <strong>Elikon Investment<\/strong>, and <strong>Talon Capital<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-funding-amp-strategic-allocation\">Funding &amp; Strategic Allocation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Use of Proceeds<\/th><th>Focus Area<\/th><\/tr><\/thead><tbody><tr><td><strong>Clinical Development<\/strong><\/td><td>Pivotal trials for lead candidate Ori-C101<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>Regulatory filings and international trial sites<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Scaling multi-mechanism CAR-T R&amp;D (secreted, rapid-manufacture, in vivo)<\/td><\/tr><tr><td><strong>Capital Markets Prep<\/strong><\/td><td>IPO readiness and governance infrastructure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-asset-ori-c101-a-potential-global-first-for-hcc\">Lead Asset: Ori-C101 \u2013 A Potential Global First for HCC<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapy Type:<\/strong> Autologous CAR-T cell therapy<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>GPC3<\/strong> (glypican-3), highly expressed in hepatocellular carcinoma (HCC)<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Advanced <strong>hepatocellular carcinoma (HCC)<\/strong> \u2014 the most common form of primary liver cancer<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Completed <strong>investigator-initiated trials (IITs)<\/strong>; advancing to <strong>pivotal registrational studies<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> On track to become the <strong>world\u2019s first approved CAR-T therapy for HCC<\/strong>, addressing a major unmet need in oncology<\/li>\n<\/ul>\n\n\n\n<p>Early clinical data from IITs demonstrated <strong>encouraging tumor response and manageable safety<\/strong>, supporting accelerated development under China\u2019s breakthrough therapy pathways.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-platform-amp-pipeline-depth\">Platform &amp; Pipeline Depth<\/h2>\n\n\n\n<p>Beyond Ori-C101, Oricell has built a <strong>full-stack CAR-T technology platform<\/strong> capable of generating:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Multi-target CAR-Ts<\/strong> for solid tumors<\/li>\n\n\n\n<li><strong>Secreted cytokine-enhanced constructs<\/strong> to modulate the tumor microenvironment<\/li>\n\n\n\n<li><strong>Rapid-manufacturing processes<\/strong> (under 7 days) to improve accessibility<\/li>\n\n\n\n<li><strong>In vivo CAR-T programs<\/strong> leveraging novel delivery vectors<\/li>\n<\/ul>\n\n\n\n<p>This pipeline positions Oricell at the forefront of <strong>solid-tumor CAR-T innovation<\/strong>, a field historically dominated by hematologic indications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investor-confidence-amp-market-context\">Investor Confidence &amp; Market Context<\/h2>\n\n\n\n<p>The oversubscribed round reflects strong institutional appetite for <strong>China-based cell therapy innovators<\/strong> with global potential. With over <strong>400,000 new HCC cases annually in China alone<\/strong> and limited effective systemic options for advanced disease, a successful CAR-T approval could command significant market share and premium pricing.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical timelines, regulatory outcomes, and commercial potential. Actual results may differ due to scientific, regulatory, and market risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[21,77,113],"class_list":["post-62785","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-car-t","tag-cell-therapy","tag-oricell-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has raised over USD 110 million in a pre-IPO financing round. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with additional participation from an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62785\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer\" \/>\n<meta property=\"og:description\" content=\"Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has raised over USD 110 million in a pre-IPO financing round. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with additional participation from an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62785\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-10T05:21:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-10T05:21:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62785#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62785\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer\",\"datePublished\":\"2026-04-10T05:21:29+00:00\",\"dateModified\":\"2026-04-10T05:21:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62785\"},\"wordCount\":359,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CAR-T\",\"Cell-therapy\",\"Oricell Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62785#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62785\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62785\",\"name\":\"Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-10T05:21:29+00:00\",\"dateModified\":\"2026-04-10T05:21:30+00:00\",\"description\":\"Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has raised over USD 110 million in a pre-IPO financing round. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with additional participation from an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62785#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62785\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62785#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has raised over USD 110 million in a pre-IPO financing round. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with additional participation from an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62785","og_locale":"en_US","og_type":"article","og_title":"Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer","og_description":"Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has raised over USD 110 million in a pre-IPO financing round. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with additional participation from an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.","og_url":"https:\/\/flcube.com\/?p=62785","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-10T05:21:29+00:00","article_modified_time":"2026-04-10T05:21:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62785#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62785"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer","datePublished":"2026-04-10T05:21:29+00:00","dateModified":"2026-04-10T05:21:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62785"},"wordCount":359,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CAR-T","Cell-therapy","Oricell Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62785#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62785","url":"https:\/\/flcube.com\/?p=62785","name":"Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-10T05:21:29+00:00","dateModified":"2026-04-10T05:21:30+00:00","description":"Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has raised over USD 110 million in a pre-IPO financing round. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with additional participation from an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62785#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62785"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62785#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62785"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62785\/revisions"}],"predecessor-version":[{"id":62786,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62785\/revisions\/62786"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}